Personalized Medicine Market 2025–2029: Strategic Opportunities and Growth Insights

Uncover key drivers, emerging technologies, and competitive movements shaping the personalized medicine market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Personalized Medicine Market Now And By 2029?

The sorafenib market has experienced steady expansion in recent years. Its value is anticipated to rise from $1.24 billion in 2024 to $1.29 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 3.4%. The increase observed in previous periods was largely a result of beneficial government policies and reimbursement initiatives, a rise in the approval of new medications, increased apoptosis within cancer cells, a growing occurrence of the target cancers, and expanding research efforts into sorafenib.

The sorafenib market is projected to experience consistent expansion over the upcoming years. Its value is anticipated to reach $1.5 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 3.9%. This expansion during the forecast period is driven by factors such as the rising occurrences of thyroid cancer, the general increase in cancer cases, a growing prevalence of chronic diseases, a heightened emphasis on precision medicine, and the increasing rates of liver and renal cancers. Key developments expected during this timeframe involve progress in early diagnosis and treatment, novel alternative therapies, advancements in managing hepatocellular carcinoma (HCC), technological breakthroughs in drug delivery, and improved treatments for advanced renal cell carcinoma.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19199&type=smp

Which Long-Term Drivers Are Expected To Sustain The Personalized Medicine Market?

The rising incidence of cancer is anticipated to drive expansion in the sorafenib market going forward. Cancer refers to a collection of diseases characterized by the uncontrolled proliferation and division of abnormal cells, which can potentially infiltrate and damage healthy tissues within the body. This increase in cancer cases stems from various factors, such as an aging global population, certain lifestyle decisions, exposure to environmental hazards, and improved diagnostic methods that enable earlier and more frequent detection. As a multi-kinase inhibitor, sorafenib holds a vital position in treating cancer by targeting critical signaling pathways linked to tumor development and angiogenesis, thereby offering a potent therapeutic choice for individuals suffering from advanced renal cell carcinoma and hepatocellular carcinoma. Illustratively, data from January 2023, provided by the US-based intergovernmental organization, the National Center for Biotechnology Information, indicated approximately 1,958,310 new cancer diagnoses and 609,820 cancer-related fatalities in 2023. Consequently, the growing number of cancer cases is fueling the expansion of the sorafenib market.

How Is The Personalized Medicine Market Classified By Different Segments?

The sorafenib market covered in this report is segmented –

1) By Product: Patented Drugs, Generic Drugs

2) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

3) By Application: Kidney Cancer, Liver Cancer, Thyroid Cancer

Subsegments:

1) By Patented Drugs: Nexavar

2) By Generic Drugs: Generic Sorafenib Tosylate, Other Generic Variants

What Current And Upcoming Trends Are Shaping The Personalized Medicine Market?

Leading companies within the sorafenib market are concentrating on developing innovative products, specifically sorafenib tablets as affordable generic medicines, to boost efficacy and patient compliance while addressing specific needs in cancer treatment. These affordable generic medicines provide the same therapeutic benefits as brand-name drugs but at significantly lower prices, thereby helping to reduce healthcare costs while maintaining the same clinical efficacy as their brand-name versions. For example, in June 2022, Dr. Reddy’s Laboratories, an India-based pharmaceutical manufacturer, introduced Sorafenib tablets, a generic product for treating various cancers, into the US market following approval by the US Food and Drug Administration (USFDA). This product serves as a generic alternative to Bayer’s Nexavar, utilized for managing various cancers, including those of the liver, kidney, and thyroid. The Sorafenib tablets are offered in 200 mg dosages and are presented in bottles containing 120 tablets.

Who Are The Primary Market Leaders In The Personalized Medicine Market?

Major companies operating in the sorafenib market are Pfizer Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Bristol Myers Squibb , Mylan N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Amgen Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Natco Pharma, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/sorafenib-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Personalized Medicine Market?

North America was the largest region in the sorafenib market in 2024. The regions covered in the sorafenib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=19199&type=smp

Browse Through More Reports Similar to the Global Personalized Medicine Market 2025, By The Business Research Company

Generic Pharmaceuticals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

Branded Generics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Specialty Generics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795